Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20(+) tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: van der Horst, Hilma J., de Jonge, A. Vera, Hiemstra, Ida H., Gelderloos, Anne T., Berry, Daniella R. A. I., Hijmering, Nathalie J., van Essen, Hendrik F., de Jong, Daphne, Chamuleau, Martine E. D., Zweegman, Sonja, Breij, Esther C. W., Roemer, Margaretha G. M., Mutis, Tuna
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7892878/
https://ncbi.nlm.nih.gov/pubmed/33602901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00430-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados